SEC Filing Madrigal Pharmaceuticals.

$ 22.50

5 (247) In stock

SEC Filing - Acadia Pharmaceuticals Inc.

B. Riley Securities Downgrades Madrigal Pharmaceuticals (MDGL)

DEF 14A

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down to $283.23

Madrigal Pharmaceuticals expands patient access to Resmetirom trial - Drug Discovery and Development

MDGL / Madrigal Pharmaceuticals, Inc. - Put/Call Ratio, Options Sentiment, Unusual Options Activity

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

MDGL / Madrigal Pharmaceuticals, Inc. - Put/Call Ratio, Options Sentiment, Unusual Options Activity

Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™